Lehmann EW, Torekov SS. Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance? Cardiovasc Res. 2021;117(10):e120-2.
Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390–403.
Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20:5–21.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Mol Metab. 2021;46: 101102.
Mayendraraj A, Rosenkilde MM, Gasbjerg LS. GLP-1 and GIP receptor signaling in beta cells–a review of receptor interactions and co-stimulation. Peptides. 2022;151:170749.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–705.
Madsbad S. Review of head-to‐head comparisons of glucagon‐like peptide‐1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317–32.
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Reviews Endocrinol. 2012;8(12):728–42.
Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf. 2015;14(2):207–18.
Nauck MA, Friedrich N. Do GLP-1–based therapies increase cancer risk? Diabetes Care. 2013;36(Suppl 2):S245.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Zafar I, Unar A, Khan NU, Abalkhail A, Jamal A. Molecular biology in the exabyte era: taming the data deluge for biological revelation and clinical transformation. Comput Biol Chem. 2025. https://doi.org/10.1016/j.compbiolchem.2025.108535
Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13092025.
Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, Gad M, Al-Husseini M, Saad A. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22(9):998–1009.
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
Kumar A, Gangwar R, Ahmad Zargar A, Kumar R, Sharma A. Prevalence of diabetes in india: A review of IDF diabetes atlas 10th edition. Curr Diabetes Rev. 2024;20(1):105–14.
Keivanlou M-H, Amini-Salehi E, Sattari N, Hashemi M, Saberian P, Prabhu SV, Javid M, Mirdamadi A, Heidarzad F, Bakhshi A. Gut microbiota interventions in type 2 diabetes mellitus: an umbrella review of glycemic indices. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2024;18(8): 103110.
Keivanlou M-H, Amini-Salehi E, Hassanipour S, Zare R, Mohammadi-Vajari E, Hashemi M, Salari A, Porteghali P. The value of microbiome-targeted therapy on lipid indices of patients with type 2 diabetes mellitus: an umbrella meta-analysis of randomized controlled trials. Curr Diabetes Rev. 2025;21(1):E180-124225761.
Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. eClinicalMedicine. 2025. https://doi.org/10.1016/j.eclinm.2025.103363.
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastroenterology. 2011;141(1):150–6.
Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595–604.
Huang X, Wu Y, Ni Y, Xu H, He Y. Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021. Front Public Health. 2025;13: 1515797.
Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight/obesity. JAMA Oncol. 2024;10(2):256–8.
Krishnan A, Hadi Y, Hutson WR, Thakkar S, Singh S. Glucagon-like peptide 1–based therapies and risk of pancreatic cancer in patients with diabetes and obesity. Pancreas. 2022;51(10):1398–403.
Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology. 2024. https://doi.org/10.1053/j.gastro.2024.04.029.
Koehler JA, Baggio LL, Yusta B, Longuet C, Rowland KJ, Cao X, Holland D, Brubaker PL, Drucker DJ. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab. 2015;21(3):379–91.
Khatoon R, Ghani M, Shahzad S, Siddiqa M, Azmat M, Zafar I, Shafiq S. Phytochemical profiling and bioactive potential of momordica balsamina seed extracts for antidiabetic activity and antioxidant potential. Indus J Biosci Res. 2025;3(2):564–76.
Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine. 2019;66:157–65.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Group P-P: preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Reviews. 2015;4:1–9.
Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14(1):1–10.
Lo CK-L, Mertz D, Loeb M. Newcastle-ottawa scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:1–5.
Schmidt L, Shokraneh F, Steinhausen K, Adams CE. Introducing RAPTOR: revman parsing tool for reviewers. Syst Rev. 2019;8: 1–4.
Htoo PT, Buse JB, Gokhale M, Marquis MA, Pate V, Stürmer T. Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. Eur J Clin Pharmacol. 2016;72:1013–23.
Wang J, Kim CH. Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases. Endocr Res. 2022;47(1):18–25.
Hsieh TYJ, Lu C, Lee G-Y, Wei JC-C. Comparative analysis of GLP-1 receptor agonists versus metformin on cancer outcomes in patients with polycystic ovarian syndrome: a real-world multi-center cohort study in the United States. JCO Oncol Pract. 2024. https://doi.org/10.1200/OP.2024.20.10_suppl.402.
Abrahami D, Yin H, Oriana H, Pollak MN, Azoulay L. Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes. Epidemiology. 2018;29(2):246–53.
Sun Y, Liu Y, Dian Y, Zeng F, Deng G, Lei S. Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials. Int J Surg. 2024. https://doi.org/10.1097/JS9.0000000000001514
Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024;7(7):e2421305–2421305.
Figlioli G, Piovani D, Peppas S, Pugliese N, Hassan C, Repici A, Lleo A, Aghemo A, Bonovas S. Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2024. https://doi.org/10.1016/j.phrs.2024.107401.
Zietek T, Rath E. Inflammation meets metabolic disease: gut feeling mediated by GLP-1. Front Immunol. 2016;7:154.
Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2018;15(11):671–82.
Liu Y, Zhang X, Chai S, Zhao X, Ji L. Risk of malignant neoplasia with glucagon-like peptide‐1 receptor agonist treatment in patients with type 2 diabetes: a meta‐analysis. J Diabetes Res. 2019;2019(1):1534365.
Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y, Yasu T, Harasawa H. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2017;43(5):430–7.
Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol. 2024;9(10):957–64.
Camilleri M, Lupianez-Merly C. Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice. Am J Gastroenterol. 2022:10.14309.